Skip to main content
Premium Trial:

Request an Annual Quote

Donald Steen, Paul Queally, Keith Dionne, Fritz Frickel, Jeffrey Williams, David Strack, Neal Harte, Christopher Dick

Premium

Donald Steen joins AmeriPath as chairman of the board, replacing Paul Queally, who has been elected chairman of the executive committee. Steen is chairman of United Surgical Partners and serves on the board of Horizon Health and Kinetic Concepts. AmeriPath provides cancer diagnostics, genomics, and related information services and provides clinical trial and research development support to firms involved in developing new cancer and genomic diagnostics and therapeutics.


Keith Dionne joins Alantos Pharmaceuticals of Heidelberg, Germany, as chairman and CEO, the company said last week. Previously, he was at Millennium Pharmaceuticals, where he was vice president of research and development strategy and vice president and general manager for technology business. Dionne holds a PhD in chemical engineering and an MS in techno-logy policy from the Massachusetts Institute of Technology. Acting CEO and CSO Fritz Frickel becomes the company’s executive vice president of research and development.


Jeffrey Williams resigned as president of Genomic Solutions and as a member of the Harvard Bioscience board of directors to become CEO at another company. His position on the board will not be replaced. David Strack becomes president of Genomic Solutions, the parent company Harvard Bioscience said last week. He was previously vice president of sales and marketing at Genomic Solutions and will remain president of HBIO’s subsidiary Union Biometrica. Additionally, Neal Harte has joined the HBIO board, replacing Christopher Dick, who resigned. Neal was previously executive vice president and vice chairman of Vitale, Caturano and Company, a Boston, Mass.-based accounting firm.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.